Deals this week: Bristol-Myers Squibb, Seres Therapeutics, Flexion Therapeutics

9th June 2016 (Last Updated June 9th, 2016 18:30)

Bristol-Myers Squibb has entered a clinical research agreement with University of Texas MD Anderson Cancer Centre to further investigate new strategies for treating lung cancer, using Bristol-Myers Squibb’s immuno-oncology agents Opdivo and Yervoy.

BMS

Bristol-Myers Squibb has entered a clinical research agreement with University of Texas MD Anderson Cancer Centre to further investigate new strategies for treating lung cancer, using Bristol-Myers Squibb's immuno-oncology agents Opdivo and Yervoy.

Pursuant to the agreement, both partners will jointly utilise MD Anderson's immunotherapy platform for the preclinical and clinical testing of drugs individually or in combinations.

Bristol-Myers Squibb will use these findings to develop new therapeutic combination for future clinical studies on next-generation immune oncology drugs.

Seres Therapeutics and Mayo Clinic have entered a research agreement to identify and develop new microbiome therapeutic candidates for liver disease.

According to the agreement, Mayo Clinic Professor Nicholas F. LaRusso will collaborate with Seres Therapeutics scientists to study the role of microbiome, as well as perform clinical and preclinical studies to identify and develop novel microbiome therapeutic drugs for Primary Sclerosing Cholangitis, non-alcoholic steatohepatitis and other liver diseases.

Flexion Therapeutics has announced it will raise gross proceeds of $60m through the public offering of its common stock shares.

The company plans to use the proceeds partly to fund the new drug application (NDA) submission, marketing and commercialisation activities for Zilretta, for general corporate purposes, partly to in-license, acquire or invest in complementary businesses, technologies, products or assets, and to invest in short-term and intermediate-term, interest-bearing obligations, investment-grade instruments and certificates of deposit or guaranteed obligations of the US government.

Vedanta Biosciences plans to accelerate infectious and autoimmune disease programmes and scale up its technology platform through the funds raised from a venture financing round.

"Pursuant to the agreement, both partners will jointly utilise MD Anderson's immunotherapy platform for the preclinical and clinical testing of drugs individually or in combinations."

The company has raised $50m in the financing round, which was led by Rock Springs Capital, Invesco Asset Management, Health for Life Capital (Seventure Partners) and Puretech Health.

The Medicines Company has priced the private placement of 2.75% convertible senior notes due on 15 July 2023.

The company has announced that it has granted an option to the initial purchasers to purchase up to an additional $52.5m in aggregate principal amount of the notes to raise net proceeds of approximately $339.7m, or $390m if options for additional notes purchase are exercised.

The company plans to use part of the proceeds to repurchase 1.375% convertible notes due by 2017 in privately negotiated transactions, through one of the initial purchasers and another part for general corporate purposes, R&D expenditures and to increase the working capital.


Image: Bristol-Myers Squibb has entered a clinical research agreement with University of Texas MD Anderson Cancer Centre. Photo: Courtesy of Sue Adair.